FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next
An FDA advisory committee recently voted to recommend allowing six specific peptides to be available through compounding pharmacies. These compounds, which include BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, have grown in popularity among wellness advocates, athletes, and some medical professionals. Proponents suggest they assist with injury recovery, inflammation reduction, and metabolic support, while critics point to a lack of long-term clinical safety data and concerns regarding potential side effects.
Despite the committee's vote, these substances remain in a regulatory waiting period. The FDA has not yet formally adopted the recommendations, meaning their legal status regarding pharmacy compounding does not change immediately. The agency must follow a formal rule-making process that involves a public notice and comment period before these ingredients can be officially added to the 503A Bulks List. Industry experts suggest this procedure could take more than a year to complete.
Some committee members and advocates highlight that these compounds currently circulate within an unregulated gray market where consumers purchase products online without medical supervision. By allowing compounding pharmacies to prepare these drugs, proponents argue that patients gain access to safer, regulated versions of these substances under a physician's care. However, other experts on the panel expressed skepticism, arguing that the decision prioritizes market demand over established scientific research.
There is speculation that US Health and Human Services Secretary Robert F. Kennedy Jr. might intervene to speed up the process. Kennedy has previously stated his interest in peptides, leading some observers to believe the agency could introduce enforcement discretion, allowing pharmacies to begin compounding the substances before the final rule is published. For now, the future of these six peptides rests with the FDA's final administrative response and potential shifts in federal oversight.